On standalone basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Pfizer has increased 8.28% to Rs 591.91 crore. Operating profit margin has jumped from 34.65% to 38.43%, leading to 20.10% rise in operating profit to Rs 227.50 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 16.42% to 11.78%. Purchase of finished goods cost rose from 17.40% to 23.27%. Employee cost decreased from 13.91% to 13.83%. Other expenses fell from 17.18% to 13.18%. Other income fell 40.66% to Rs 44.58 crore. PBIDT rose 2.84% to Rs 272.08 crore. Provision for interest fell 61.29% to Rs 2.69 crore. Loan funds rose to Rs 40.78 crore as of 31 March 2025 from Rs 40.19 crore as of 31 March 2024. Inventories rose to Rs 475.92 crore as of 31 March 2025 from Rs 433.69 crore as of 31 March 2024. Sundry debtors were higher at Rs 193.09 crore as of 31 March 2025 compared to Rs 187.61 crore as of 31 March 2024. Cash and bank balance rose to Rs 2,800.98 crore as of 31 March 2025 from Rs 2,046.71 crore as of 31 March 2024. PBDT rose 4.57% to Rs 269.39 crore. Provision for depreciation rose 19.27% to Rs 16.4 crore. Fixed assets increased to Rs 179.46 crore as of 31 March 2025 from Rs 151.35 crore as of 31 March 2024. Intangible assets declined from Rs 561.76 crore to Rs 551.80 crore. Profit before tax grew 3.74% to Rs 252.99 crore. Provision for tax was expense of Rs 94.86 crore, compared to Rs 65 crore. Effective tax rate was 22.28% compared to 26.65%. Profit after tax rose 85.03% to Rs 330.94 crore. Equity capital stood at Rs 45.75 crore as of 31 March 2025 to Rs 45.75 crore as of 31 March 2024. Per share face Value remained same at Rs 10.00. Promoters’ stake was 63.92% as of 31 March 2025 ,compared to 63.92% as of 31 March 2024 .
Full year results analysis
Net sales (including other operating income) of Pfizer has increased 4.02% to Rs 2,281.35 crore. Operating profit margin has jumped from 28.97% to 32.45%, leading to 16.52% rise in operating profit to Rs 740.23 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.23% to 12.07%. Purchase of finished goods cost rose from 21.25% to 22.73%. Employee cost increased from 15.77% to 16.46%. Other expenses fell from 18.93% to 15.93%. Other income fell 4.58% to Rs 172.25 crore. PBIDT rose 11.85% to Rs 912.48 crore. Provision for interest fell 45.43% to Rs 8.41 crore. Loan funds rose to Rs 40.78 crore as of 31 March 2025 from Rs 40.19 crore as of 31 March 2024. Inventories rose to Rs 475.92 crore as of 31 March 2025 from Rs 433.69 crore as of 31 March 2024. Sundry debtors were higher at Rs 193.09 crore as of 31 March 2025 compared to Rs 187.61 crore as of 31 March 2024. Cash and bank balance rose to Rs 2,800.98 crore as of 31 March 2025 from Rs 2,046.71 crore as of 31 March 2024. PBDT rose 12.95% to Rs 904.07 crore. Provision for depreciation down 2.39% to Rs 60.79 crore. Fixed assets increased to Rs 179.46 crore as of 31 March 2025 from Rs 151.35 crore as of 31 March 2024. Intangible assets declined from Rs 561.76 crore to Rs 551.80 crore. Profit before tax grew 14.25% to Rs 843.28 crore. Extraordinary items were increased to Rs 172.81 crore. Provision for tax was expense of Rs 248.49 crore, compared to Rs 194.74 crore. Effective tax rate was 24.46% compared to 26.10%. Profit after tax rose 39.23% to Rs 767.60 crore. Equity capital stood at Rs 45.75 crore as of 31 March 2025 to Rs 45.75 crore as of 31 March 2024. Per share face Value remained same at Rs 10.00. Promoters’ stake was 63.92% as of 31 March 2025 ,compared to 63.92% as of 31 March 2024 . Cash flow from operating activities increased to Rs 659.75 crore for year ended March 2025 from Rs 256.84 crore for year ended March 2024. Cash flow used in acquiring fixed assets during the year ended March 2025 stood at Rs 28.15 crore, compared to Rs 18.93 crore during the year ended March 2024. Other Highlights
The board has recommended a total dividend of Rs 165 per equity
share of Rs 10 each for the financial year ended March 31, 2025. This includes
a final dividend of Rs 35 per share, a special dividend of Rs 100 per share to
commemorate Pfizer’s 75th year in India, and an additional special dividend of
Rs 30 per share arising from the gain on the transfer of leasehold land and the
building constructed on it. Record date for the purpose is July 9, 2025.
| Pfizer : Standalone Results | | Quarter ended | Year ended |
|---|
| Particulars | 202503 | 202403 | Var.(%) | 202503 | 202403 | Var.(%) |
|---|
| Net Sales (including other operating income) | 591.91 | 546.63 | 8.28 | 2,281.35 | 2,193.17 | 4.02 | | OPM (%) | 38.43 | 34.65 | 378 bps | 32.45 | 28.97 | 348 bps | | OP | 227.50 | 189.43 | 20.10 | 740.23 | 635.30 | 16.52 | | Other Inc. | 44.58 | 75.13 | -40.66 | 172.25 | 180.51 | -4.58 | | PBIDT | 272.08 | 264.56 | 2.84 | 912.48 | 815.81 | 11.85 | | Interest | 2.69 | 6.95 | -61.29 | 8.41 | 15.41 | -45.43 | | PBDT | 269.39 | 257.61 | 4.57 | 904.07 | 800.40 | 12.95 | | Depreciation | 16.4 | 13.75 | 19.27 | 60.79 | 62.28 | -2.39 | | PBT | 252.99 | 243.86 | 3.74 | 843.28 | 738.12 | 14.25 | | PBT before EO | 252.99 | 243.86 | 3.74 | 843.28 | 738.12 | 14.25 | | EO Income | 172.81 | 0 | - | 172.81 | 7.95 | 2,073.71 | | PBT after EO | 425.8 | 243.86 | 74.61 | 1016.09 | 746.07 | 36.19 | | Taxation | 94.86 | 65 | 45.94 | 248.49 | 194.74 | 27.60 | | PAT | 330.94 | 178.86 | 85.03 | 767.6 | 551.33 | 39.23 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 330.94 | 178.86 | 85.03 | 767.6 | 551.33 | 39.23 | | EPS (Rs)* | 42.98 | 39.10 | 9.94 | 139.25 | 119.23 | 16.79 | | | * EPS is on current equity of Rs 45.75 crore, Face value of Rs 10, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|